Chronische myeloische Leukämie

Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809–1820

Cortes J, Kantarjian HM, Kim DW et al (2008) Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to imatinib. Blood 112:401

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

Hehlmann R, Hochhaus A, Baccarani M for the European LeukemiaNet (2007) Chronic myeloid leukaemia. Lancet 370:342–350

Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200–1206

Hochhaus A, Druker B, Sawyers C et al (2008) Favorable longterm follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferonalpha treatment. Blood 111:1039–1043

Hochhaus A, Kreil S, Corbin AS et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196

Hochhaus A, O’Brien SG, Guilhot F et al (2009) Sixyear followup of patients receiving imatinib for the firstline treatment of chronic myeloid leukemia. Leukemia (Epub ahead of print)

Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37

Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423–1432

Jabbour E, Kantarjian HM, Jones D et al (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113:2154–2160

Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542–2551

Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546

O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and ­intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212